Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer

2006 ◽  
Vol 65 (4) ◽  
pp. 1155-1160 ◽  
Author(s):  
Thomas A. Buchholz ◽  
Eric A. Strom ◽  
Mary Jane Oswald ◽  
George H. Perkins ◽  
Julia Oh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Chest Wall ◽  
Locally Advanced ◽  
Prospective Trial ◽  
Once Daily ◽  
Randomized Prospective Trial

scholarly journals A Randomized Prospective Trial of Radical (Halsted) Mastectomy Versus Modified Radical Mastectomy in 311 Breast Cancer Patients

1983 ◽  
Vol 198 (2) ◽  
pp. 207-212 ◽  
Author(s):  
WILLIAM A. MADDOX ◽  
JOHN T. CARPENTER ◽  
HENRY L. LAWS ◽  
S. J. SOONG ◽  
GRETCHEN CLOUD ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Prospective Trial ◽  
Radical Mastectomy ◽  
Breast Cancer Patients ◽  
Modified Radical Mastectomy ◽  
Randomized Prospective Trial

Bevacizumab and oral chemotherapy for patients with lymphangitic breast cancer: A phase II randomized study of bevacizumab with sequential versus concurrent oral vinorelbine plus capecitabine

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 1031-1031
Author(s):  
M. A. Locatelli ◽  
G. Curigliano ◽  
L. Fumagalli ◽  
R. Ghisini ◽  
P. Mancuso ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Chest Wall ◽  
Phase Ii ◽  
Biological Effects ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Antiangiogenic Agents ◽  
Surrogate Markers ◽  
Oral Vinorelbine ◽  
Antiangiogenic Activity

1031 Background: Antiangiogenic agents are most likely to be effective in patients (pts) with an extensive cutaneous neo-angiogenic trait of disease. There is a compelling need to monitor the biological activity of such agents and identify markers of efficacy. Methods: We evaluated the activity and biological effects of bevacizumab (B) (15 mg/kg, iv q 3 weeks) in a phase II randomized trial in pts with locally advanced breast cancer (BC) with lymphangitic spread to the chest wall. Primary aim was to assess activity and toxicity of B administered alone followed by sequential oral vinorelbine (V) plus capecitabine (C) (arm A) or with concurrent V plus C (arm B). Secondary aim was to evaluate predictive role of circulating progenitor cells (CECs) and progenitor endothelial cells (CEPs) as surrogate markers of antiangiogenic activity. We collected blood samples of all pts at baseline, at day 12, 42, and at progression. Results: Planned accrual was of 43 pts of whom 23 were enrolled (9 pts in arm A; 14 pts in arm B). Median age was 51 years (range 35–68). Most of the pts had a “triple negative” phenotype [19/23 (82%)]. 10/23 pts (43%) received ≥ 2 previous lines of chemotherapy. 19 pts (82 %) are evaluable for response and all 23 pts are evaluable for toxicity. We observed 5 PR (45%) and 6 SD (55%) in arm B. In arm A, while on B alone, 6 (75%) of the pts had PD and 2 (25%) had a short term SD. Adding VC to B 2 PR (25%), 3 SD (37.5%), and 3 PD (37.5%) were observed. Toxicity profile was typical for use of B (hypertension). The absolute mean number of CECs was 158/ml (range 45–461) (n = 23) at baseline, 116/ml at +12 (range 47–275), and 194/ml at +42 (range 36–891). Mean absolute value of CEPs was 270 (range 28–1060) at baseline, 245/ml at D+12 (range 14–981), and 143/ml (range 5–610) at D+42. The fraction of apoptotic/necrotic CECs was 54±19% at baseline, 64±21 at+12, and 52±18 at+42. Conclusions: Preliminary data showed that B alone is not an effective treatment in pts with lymphangitic spread of BC to the chest wall. Additional data on CECs and CEPs are needed to clarify their potential usefulness as a surrogate markers of antiangiogenic activity of B-based regimen. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document